Loading...
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet...
Na minha lista:
| Udgivet i: | J Blood Med |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5602457/ https://ncbi.nlm.nih.gov/pubmed/28979172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S121550 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|